Recent Advances in Multiple Myeloma: Insights from Experts at University of Pennsylvania : Episode 5
Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.
EP: 1.Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 2.Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM
EP: 3.Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 4.Consolidation and Maintenance Therapy in Transplant-Eligible NDMM
Now Viewing
EP: 5.Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma
EP: 6.Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM
EP: 7.Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability
EP: 8.Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
EP: 9.Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM
EP: 10.Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM
EP: 11.University of Pennsylvania Experts Discuss Treatment Options in Transplant-Eligible and -Ineligible Newly Diagnosed Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
